Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XT-150 in osteoarthritic knee pain
NCT03282149Phase 1Completed
- Sponsor
- Xalud Therapeutics
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XT-150 in osteoarthritis (OA) (4 arms), sponsored by Xalud Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 180 days. Started Mar 2018; status: completed.
02
Drugs
XT-150
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03282149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282149.